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Abstract
Hepatitis B and C viruses (HBV/HCV) are among the leading causes of liver 
disease. HBV is a partially double-stranded circular DNA virus whose genome is 
approximately 3200 bases with four overlapping open reading frames (ORFs) and 
belongs to Hepadnaviridae family. HBV prevalence varies worldwide, with high 
rates reported in low-income countries. Approximately 90% of HBV infections are 
acute, 10% progress to chronic infection among adult patients. Although HBV can 
be prevented by immunisation, there is no licenced HCV vaccine. HCV is a positive-
sense single-stranded RNA (+ssRNA) virus belonging to Flaviviridae family. The 
HCV global epidemiology varies, with high prevalence rates reported in low-income 
countries. Approximately 80% of acutely HCV-infected individuals develop chronic 
hepatitis disease, while 20% resolve spontaneously. Both HBV and HCV infections 
can result in both acute and chronic hepatitis, ranging in severity from asymptomatic 
to a life-threatening disease. The HBV and HCV are transmitted through contact with 
contaminated blood or its products. As compared with mono-infection, HBV/HCV 
co-infection has higher risk of liver damage. Thus, individuals who have active HBV 
and HCV infections are likely to be HCV-dominant with a high HCV viral load and 
low or undetectable HBV DNA levels.
Keywords: viral hepatitis, hepatitis B virus, hepatitis C virus, epidemiology, 
pathogenesis, natural history, diagnosis, genotype, treatment, natural history
1. Hepatitis B virus
Hepatitis B virus (HBV) belongs to Orthohepadnavirus genus a member of the 
Hepadnaviridae family which includes other identified but less popular viruses such as 
Pekin duck, woodchuck, Woolly monkey hepatitis B, and ground squirrel viruses. There are 
some viral similarities in structure, size, nature, genetic replication, and ability to cause 
infection among these viruses, but HBV remains a major cause of chronic liver disease [1].
1.1 Properties
1.1.1 Structure
The HBV is a partially double stranded enveloped deoxyribonucleic acid (DNA) 
virus with an icosahedral symmetry that can be seen in three different forms and 
sizes [2]. The predominant form is a small, spherical particle (22 nm diameter), the 
other form has a diameter of 42 nm. Generally, the HBV virion is spherical, with a 
diameter of about 40–48 nm, and a length of about 3.2 kb [3]. Approximately 1014 
HBV particles per millilitre can be present in the blood of an infected individual [4].
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1.1.2 HBV genome organisation
The HBV genome is made up of a circular DNA which is partly single stranded 
and partly double stranded. The DNA is not fully double stranded; one strand is 
incomplete (short strand) whereas the other forms a full length strand (complete 
long strand). There are small molecules that are covalently linked to the 5′ end of 
each HBV DNA strand. The short strand is capped with a ribonucleic acid (RNA), 
whereas the complete long strand is linked to a viral DNA polymerase [5]. The HBV 
DNA forms a circular conformation, and the full length strand together with the 
double stands form a short sequence of triple-stranded at the 5′ ends. The HBV enve-
lope comprises three proteins namely; small (S), medium (M), and large (L) that are 
expressed on the surface of the viral particle. The S protein is the most abundant of 
the three. The gene S encodes for the HBV surface antigen (HBsAg) [6].
1.1.3 Genetic variation
The HBV unique life cycle requires an error-prone reverse transcriptase for rep-
lication which results in genetic variation in the form of genotypes, sub-genotypes, 
and mutations. The relationship between HBV genetic variation and HBV-related 
pathogenesis has been described which determines the outcome of HBV exposure. 
The HBV genome has approximately 3200 bases with four overlapping open reading 
frames (ORFs) namely: pre-S/S (surface proteins), pre-C/C (pre-core/core), X (tran-
scriptional co-activator) and P (DNA polymerase) [6, 7]. The pre-S/S ORF which 
encodes different structural envelope proteins (large, medium and small) is contained 
within the P ORF, the C ORF overlaps the P ORF by a quarter of its sequence length; 
whereas the X ORF overlap the P ORF by a third of its sequence length. From the 
above mentioned four ORFs, seven different proteins are translated [6].
1.1.4 Replication cycle
The HBV replication is initiated by the attachment of the viral particles to the 
target cells, in this instance, hepatocytes. A number of cellular receptors such as 
heparin sulfate proteoglycan (HSPG), and sodium taurocholate co-transporting 
polypeptide (NTCP) have been reported [8]. Following attachment to the hepa-
tocytes, the viral particles fuse with the host cell’s membrane and enter the cell 
through endocytosis. Following penetration into the cell, the virus uncoats releasing 
the genetic material (HBV DNA) into the cytoplasm, which is transferred into the 
nucleus through nuclear pores. In the nucleus, the genetic material is converted to 
a complete circular double stranded DNA (dsDNA) by the action of the host DNA 
polymerase. The dsDNA is then transformed into a covalently closed circular DNA 
(cccDNA) ring (an episomal viral genome) that serves as a template for transcrip-
tion of five viral RNAs [6, 9, 10]. The dsDNA is very stable and can survive in the 
host nucleus for a long time. The cellular RNA polymerase transcribes the negative 
sense single stranded DNA (−ssDNA) to form a positive sense single stranded 
RNA (+ssRNA). The newly transcribed positive RNA strand leaves the nucleus and 
migrates to the cytoplasm for protein synthesis (translation). The reverse tran-
scriptase enzyme converts the +ssRNA to form a −ssDNA (reverse transcription). 
The +ssRNA is flanked by a small fragment of DNA polymerase at the 5′ end which 
primes the reverse transcription of ¾ of the +ssRNA but unable to complete the 
transcription of the remaining third. This results in the formation of dsDNA viral 
particles containing one partially complete strand. The mature viral particles exit 
the cell through budding and invade other hepatocytes and repeat the replication 
cycle [11–13].
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1.2 Epidemiology
The HBV prevalence varies worldwide, with high rates reported in low income 
countries. The World Health Organisation (WHO) estimates that 6.1% of the African 
population, and 6.2% of the Western Pacific region are infected with HBV [1]. The 
HBV endemicity is heterogeneous due to variable multiple factors such as child vac-
cination, injection drug use, poor sensitisation campaigns among others [14].
Approximately over 250 million people are infected with HBV globally [15]. The 
risks of infection vary widely due to different behaviours that determine the rate of 
exposure. Uninfected laboratory personnel and other health-care workers are at risk 
of HBV exposure from infected patients, but the degree of risk depends on several 
factors such as the strength of their immunity, and nature of work performed [16]. 
Likewise, patients are also at risk from hospital staff when there are conducting 
their duties such as surgery, haemodialysis, and dentistry procedures.
1.3 HBV genotypes and their geographical distribution
HBV genotype plays a significant role in the clinical outcome following viral-
host interaction. There are 10 different genotypes of HBV (from A to J), that 
determine the liver disease clinical progression, prognosis, and the response to 
antiviral therapy. Genotypes A, B, C, D, and F are associated with rapid progression 
to cirrhosis and hepatocellular carcinoma. The HBV genotypes A and B are com-
monly isolated in acute HBV infected individuals [17].
The HBV genotypes geographical distribution varies from one genotype and 
subtype to the other. The variations in the HBV genotype distributions are related 
to mode and route of transmission, where vertical transmissions are associated with 
genotypes B and C [17]. The HBV genotype A is prevalent in Africa, and North 
Europe; genotypes B and C are widespread in Asia; genotype D is also common 
in Africa, some parts of Europe, and Asia; genotype E is predominantly in West 
and Central Africa; genotype F is common in America; genotype G is common in 
Western countries; genotype H is found in Central and South America; genotype I 
was reported in Vietnam and Laos; while genotype J was reported in Japan [7, 18].
1.4 Transmission
The HBV cases usually occur in parenteral drug injection use through sharing of 
infected needles and other paraphernalia. Other risk factors include: sexual contact, 
transfusion of blood and/or its products, occupational exposure (e.g. laboratory, 
and other health-care workers, surgery, dental surgery, obstetrics and gynaecology 
procedures), and use of unsterile procedure when in contact with blood or body 
fluids. The HBV transmission routes are similar to most blood-borne viruses such as 
Human immunodeficiency virus (HIV) [7]. Transmission from mother-to-child is pos-
sible; therefore, early intervention at birth is important to protect the HBV infection. 
Efforts are on-going to achieve a 90% reduction in new chronic HBV infections [19].
1.5 Natural history
The natural history of chronic HBV infection (CHBV) varies and is dependent 
of the viral virulence factors and the host’s immune response. Following expo-
sure to HBV, some individuals (0.5–1% per year) clear the HBsAg spontaneously 
but remain anti-HBV positive, with undetectable HBV DNA in serum, whereas 
the majority progress to CHBV infection. The development of CHBV infection 
is determined by a complex set of interactions between the host (e.g. age, sex, 
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immune status, and other underlying infections) and the virus (e.g. infective dose, 
co-infection with other viruses, and viral genotype) [20].
The CHBV infection is characterised by elevated serum alanine aminotransfer-
ase (ALT), serum HBV DNA, and/or hepatitis B e antigen (HBeAg), HBsAg which 
determines the phase of infection and predicts the risk of disease progression to 
hepatocellular carcinoma (HCC) [21]. Five CHBV phases (1, 2, 3, 4 and 5)  
have been described based on HBeAg, ALT, and HBV viral load [22]. Phases 1 
and 2 would be HBeAg-positive, whereas phases 3 and 4 would be considered to 
be HBeAg-negative. The chronic HBV phase 1 is also known as immune tolerance 
phase (HBeAg-positive chronic HBV infection), phase 2 (immune clearance phase 
or HBeAg-positive chronic hepatitis B), phase 3 (inactive carrier phase or HBeAg-
negative chronic HBV infection), phase 4 (reactivation phase or HBeAg-negative 
chronic hepatitis B), and phase 5 (occult HBV infection or HBsAg-negative phase). 
During the early stages of CHBV infection, the serum ALT levels are normal or 
slightly elevated whereas the HBV DNA, and hepatitis B e antigen (HBeAg) levels 
are elevated in serum. This first stage is followed by a second phase where the 
HBeAg, HBsAg, and ALTs are elevated. After varying intervals, the ALT levels 
return to normal, and the HBV DNA reach undetectable levels or suppressed to low 
levels, resulting in an inactive HBV carrier state. The fourth phase is characterised 
by fluctuation of HBV diagnostic markers that include HBV DNA, ALTs and HBV 
antibody concentrations [21, 22]. The fifth phase is characterised by the presence of 
anti-HBc antibodies, absence of HBsAg, detectable or undetectable anti-HBs anti-
bodies. Of note, not all HBV patients fit into these phases of disease progression. 
Chronic HBV infection does not always represent development of chronic hepatitis 
B disease. Thus, not all patients with HBV infection have hepatitis disease [22].
1.6 Clinical features
The possible outcome following HBV exposure depend on series of complex 
mechanisms that could lead to spontaneous clearance with detectable HBV antibod-
ies, or establishment of chronic HBV infection (described in four phases). The HBV 
incubation period varies greatly often about 2–6 months, but shorter incubation 
periods have been observed related to high infective doses. Symptoms of HBV infec-
tion may include fever, nausea, vomiting, abdominal pain, dark urine, anorexia, 
myalgia, and jaundice (is the hallmark of severe liver disease). In some cases, 
arthralgia may occur, hepatocellular damage may be detected [7, 21].
1.7 Pathogenesis
1.7.1 Acute infection
It is estimated that approximately 90% of HBV infections are acute, where about 
10% progress to chronic HBV infection among adult patients, whereas 30–50% 
for infection among under-5 children. The HBV replicates in hepatocytes follow-
ing successful entry into the cell by binding the host cellular receptors. In acute 
infection before seroconversion, the HBV viral load is high before the host immune 
response kicks in. The viral markers such HBeAg, and HBeAg are expressed on 
the host cellular cytoplasmic membrane that trigger an adaptive immune response 
(both B and T cells) [6, 23].
Within hours following HBV exposure, the host innate immune response by releas-
ing the interferon-α which modulate the immune system, and has a direct antiviral 
effect [24]. This is followed by a transient release of interleukin (IL)-6 to control the 
viral spread and virus-induced cellular apoptosis. The production of interferons and 
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other cytokines enhances the expression of major histocompatibility complex class I 
(MHC-I) that recognises the viral antigens which leads to lysis of infected hepatocytes. 
The subsequent activation of natural killer (NK) and cytotoxic killer cells may reduce 
the HBV viral load through secretion of different cytokines, which may lead to hepato-
cellular damage. An anti-inflammatory cytokine IL-10 suppresses the activation of NK 
T cells. The liver damage is less severe in the HBV acute infection [25–27].
1.7.2 Chronic infection
HBV persistence and development of chronic HBV infection is a result of 
neonatal tolerance to HBV if acquired vertically. The HBV precore antigen, HBeAg 
which crosses the placenta is able to induce neonatal tolerance to HBV ex vivo. The 
HBV adult infections have a low rate (<5%) of developing chronic HBV infection 
as compared to neonates. However, the mechanism that contributes to inadequate 
immune response a key feature of onset of chronic HBV in adults is unclear.
Of note, nearly 15–40% of HBV infected individuals are at risk of developing 
cirrhosis during their life time, and nearly 5% risk of HCC with cirrhosis. During the 
immune clearance phase (phase 2), the viral load is reduced due to the action of the 
cytotoxic T cells that destroy the infected hepatocytes. Since the action of NK and 
cytotoxic T cells in chronic HBV infection is inefficient, the destruction of hepatocytes 
happens for years which increases the possibility of reinfection [11, 15, 25, 26, 28].
The production of different HBV specific antibodies such as those against 
HBeAg, HBcAg, and HBsAg prevent the spreading of viral particles between 
hepatocytes. Ineffective viral suppression could lead to cirrhosis which is a prime 
factor for carcinogenesis. The integration of viral and host genome, and the forma-
tion of cccDNA during viral replication are essential steps towards development of 
hepatic carcinogenesis. Both B and T cell responses to HBcAg could be suppressed 
by secretion of some HBV antigens such as HBeAg, which results in inhibition of 
HBcAg-specific T cells to eliminate HBV infected hepatocytes. Likewise, increased 
levels of HBsAg also suppress the immune elimination of infected cells [9–11].
Increased risks of cirrhosis and HCC are associated with male gender, race, HIV, 
hepatitis C virus (HCV) co-infection, persistence of increased HBV viral load (high 
HBV DNA levels), HBeAg negative status, elevated ALTs, and the general impair-
ment of host immune responses.
The HBV clinical outcomes are classified into: immune-tolerant, immune clear-
ance, inactive and recovery phase. Occult HBV infection is a phenomenon that occurs 
in patients who receive HBV vaccine and/or hepatitis B immunoglobulin injection 
who may develop chronic HBV infection with PreS and/or S gene mutations. In these 
four clinical stages of HBV infection, the HBV DNA levels are high in immune toler-
ance and immune clearance stages, and become undetectable in inactive phase. HBV 
isolated from chemotherapy of immunocompromised patients show mutations in the 
PreS, S, basal core promoter (BCP) or Pre-C regions (Figure 1) (Adapted from [6]).
1.8 Laboratory diagnosis
1.8.1 Acute HBV infection
Nearly 90% of acute HBV infections in adults are self-limiting, with only a small 
proportion (<1%) progress to severe acute infection. Acute HBV infection presents 
with non-specific signs and symptoms. The HBV incubation period may be 6 weeks 
or more following exposure. Some of the signs and symptoms of acute HBV infec-
tion may include: malaise, fever, nausea, dark urine and anorexia. The majority 
of acute HBV infected individual are usually asymptomatic with elevated levels 
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of ALT, total bilirubin, and total protein. The HBsAg positive test suggest an HBV 
infection, however it is advisable to repeat the test after 6 months to determine HBV 
spontaneous resolution or establishment of chronic infection [29].
1.8.2 Chronic HBV infection
The majority of acute HBV infected individuals clear the infection spontane-
ously, whereas 5–10% progress to develop chronic HBV infection. The majority of 
chronic HBV infected individuals are at risk of developing chronic active disease 
(HBV hepatitis) which may progress to cirrhosis and hepatocellular carcinoma. 
The development of chronic HBV infection does not follow clinical phases (1–5) in 
sequential order as described above. The HBV diagnostic markers vary from one 
clinical phase to another.
1.8.2.1 Immune-tolerance phase
During the immune-tolerance phase of chronic HBV infection, the virus is 
actively replicating, but there is a reduced inflammation response. The individuals 
who get HBV infection at birth stay in this phase for decades before progressing to 
the next phases of liver disease. The laboratory diagnosis markers that characterise 
the immune-tolerance phase include: increased HBV viral load (>million copies IU/
ml), normal ALT, HBsAg positive test [22, 30].
1.8.2.2 Immune clearance phase
During the immune-active phase, the virus continues to replicate and cause 
noticeable liver damage. The host immune response activates the signalling cascade 
Figure 1. 
HBV pathogenesis and clinical outcomes.
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that leads to inflammatory response, leading to liver fibrosis. The individuals who 
were HBV susceptible during childhood stay in this phase for decades but clinical 
feature manifest in mid-thirties. During this stage, the laboratory diagnostic features 
fluctuate from HBeAg positive to negative, with detectable anti-HBe antibodies. 
Classic HBV immune-active phase is characterised by the HBeAg seroconversion 
and detection of different anti-HBV immunoglobulins. The HBeAg seroconversion is 
associated with reduced disease progression rate to development of cirrhosis and end 
stage liver disease. The laboratory detection markers include: increased ALT levels, 
four-fold increase in HBV viral load, positive HBeAg, and liver fibrosis [22].
1.8.2.3 Inactive carrier phase
In this phase, the anti-HBe antibodies are detectable, whereas the ALT levels 
return to normal, and HBV viral load is suppressed and may be undetectable. The 
extent of liver damage depends on an inflammatory immune response, but liver 
fibrosis is noticeable if it was observed in the previous stage of liver disease. The 
majority (nearly 80%) of chronic HBV infected patients remain in this stage whereas 
nearly 20% may revert to the immune-tolerance phase. Some of the laboratory 
diagnostic markers of this stage include: Normal ALT, negative HBeAg, reduced or 
undetectable HBV viral load (<2000 copies IU/ml), and variable liver fibrosis [22].
1.8.2.4 Reactivation phase
This phase is also known as the immune reactivation phase where the chronic 
HBV is very active with detectable anti-HBe antibodies. Some of the diagnostic 
markers include: increased HBV viral load, elevated ALT, negative HBeAg, moder-
ate-to-severe liver fibrosis, sometimes cirrhosis, and hepatocellular carcinoma. In 
this phase, people have seroconverted to anti-HBe positive, but their chronic HBV is 
very active. The ALT levels and HBV viral load are elevated. The liver inflammation 
and fibrosis levels are moderate to severe [22].
1.8.2.5 Occult HBV infection
This phase is also known as HBsAg-negative phase. During this phase the viral 
detection markers such as HBsAg, anti-HBs, and HBV DNA are usually negative. 
The anti-HBc antibodies are positive, and in rare cases, the anti-HBs could be posi-
tive. The serum ALT levels are usually normal, with detectable cccDNA copies [22].
1.9 Treatment, prevention, and control
The treatment and management efforts of HBV infection are aimed at reducing 
the incidence rates, prevent development of chronic HBV disease, progression to 
HCC, and obviously death from HBV-related liver disease. The decision to treat is 
based on clinical assessment of phases of HBV infection based primarily on the bio-
chemical, virological, serological investigations, and the stage of liver disease [22].
Historically, the interferon-based therapy has been the principal treatment 
option for HBV infection. The current HBV treatment guidelines recommend 
treating patients with increased viral load, decompensated liver cirrhosis, and 
HCC. Treatment is less favourable in HBV infected individuals classified as belonging 
to first phase chronic HBV infection. The recommended standard treatment for HBV 
infection is the nucleoside analogues (NAs) and/or IFN-based therapy. The response 
to IFN-based therapy is robust which results in loss of HBeAg and HBsAg as opposed 
to NA monotherapy. However, IFN is less efficient at suppressing viral replication and 
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is reported to be associated with adverse effects compared to the NAs. The IFN-α has a 
direct antiviral effect through inhibition of viral assembly [8, 31].
The pegylated IFN-α administered parenterally, and the NAs (Entecavir 
and Tenofovir) are the first line antiviral drugs recommended for chronic HBV 
treatment. These drugs are hardly available in low income countries due to high 
costs. The most widely antiviral drug for HBV treatment is lamivudine which is a 
nucleoside analogue that inhibits the synthesis of HBV DNA ex vivo. The lamivu-
dine course has resulted in a marked reduction in viral DNA, normal ALT levels, 
HBeAg-positive cases seroconverting to become anti-HBe positive. Other antiviral 
drugs that have been used to treat HBV infection include adefovir, emtricitabine, 
telbivudine, and clevudine. For end stage liver disease such as HCC, liver trans-
plantation is recommended. There is an urgent need to develop alternative HBV 
therapeutic agents that can successfully suppress HBV replication and decrease the 
risk of disease progression to fibrosis and HCC [8, 31].
Several approaches can be employed for the prevention and control of HCV 
infection. Screening of blood donations has significantly reduced the risks of HBV 
transmission through transfusion of blood and/or its products [32]. Modification 
of risk behaviours proves to be an effective measure to prevent HBV transmission. 
Some essential approaches include voiding contact with blood and body fluids, 
practicing safe sexual contact, avoiding drug use (either injecting or snorting), 
and use of sterile needles when body piercing and acupunctures. The implementa-
tion of health and safety policies that include wearing personal protective equip-
ment when performing risky procedures in the hospital or during accidents and 
emergencies [22].
Herd immunity can be provided through incorporation of HBV vaccine in 
the child immunisation schedule. Other important approaches to prevent HBV 
infection include: antenatal screening for identification of carrier mothers, 
and universal infant and adolescent vaccination. If universal vaccination is not 
implemented yet, HBV vaccine should be given to other groups at special risk of 
HBV exposure.
1.10 Vaccination
Hepatitis B is a vaccine preventable disease. In 1965, Dr. Baruch Blumberg and 
his team discovered the HBV vaccine which prevents the establishment of HBV 
infection and liver cancer [33].
1.10.1 Active immunisation
The current HBV vaccine is given in three doses as follows: first dose given 
within 24 hours, second dose given 1 month later, and a third booster dose given 
at 6 months of age. The HBV vaccine elicits humoral immune response that is 
mediated by secreted anti-HBs antibodies. Such an antibody-mediated response is 
influenced by several factors including age, sex, immune status, and underlined 
pathological conditions. High seroconversion rates of >90% are seen in young 
female adults as opposed to their male counterparts or older men, whereas lower 
rates are observed in immunosuppressed individuals [34].
The HBV vaccine was made available since 1982. In 1991, the WHO recom-
mended that each country adopt and implement universal HBV vaccination pro-
gramme. HBV vaccine is included in the new-born immunisation schedule where 
first dose is given shortly after birth, second dose at 1–2 months of age, and third 
dose at 6–18 months of age. A child born to a HBV-positive mother should receive 
the HBV vaccine and HBIG combination as early as within 12 hours after birth to 
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protect baby from HBV infection. The vaccine may cause swelling, soreness and 
redness on the site of injection, and a mild fever [35, 36].
1.10.2 Passive immunisation
The plasma-derived hepatitis B vaccine was licenced for human use in 1981. 
Hepatitis B immunoglobulin (HBIG) is an anti-HBs prepared from plasma of 
donors with high titres of antibodies of the HBsAg. The administration of anti-HBV 
immunoglobulins induces an adaptive immune response. Since the HBIG contains 
anti-HBV immunoglobulins, it offers an immediate short-term protection in risk 
population who have not yet received HBV vaccine. The HBIG half-life is estimated 
at 3 weeks, but long-term protection can be achieved by a combination of HBIG and 
HBV vaccine at the time of HBIG initial administration. Therefore, an HBIG booster 
dose is not necessary when a HBV vaccine is administered concurrently with HBIG 
[37, 38]. The HBIG dose of 300–500 IU in 3 ml is administered either intramuscularly 
(IM) or intravenously as a post-exposure prophylaxis, given to babies born to infected 
mothers, or prevention of the establishment of chronic HBV infection in liver trans-
plants. HBIG should be administered 24–48 hours after a potential exposure to HBV, 
and a second dose 4 weeks later. An absolute protection against HBV is unlikely to be 
achieved but a vaccine efficacy of 76% has been reported, and the protection could 
last for at least 22 years [38]. In babies, a 6 month course of HBIG is initiated that 
offers nearly 70% efficacy. High rates (nearly 90%) are achieved when combining 
HBIG and HBV vaccine.
The HBIG side effects include allergic reactions, back pain, muscle pain, nausea, 
and general body pain.
1.10.3 Who should get vaccinated?
HBV vaccination is aimed at preventing HBV transmission to uninfected 
individuals, and ultimately eradicating the virus from the population. A small 
subset of HBV exposed individuals exist who have persistent HBV infection, could 
have undetectable or carry low levels of the HBV DNA; and are termed ‘inactive 
HBV carriers.’ The HBV carrier state is a potential reservoir for HBV transmission 
through contact with the infected body fluids.
The HBV vaccination is recommended in the following [16]:
• Newly born babies who could become long-term HBV carriers if not protected 
immediately after birth
• Commercial sex workers
• Intravenous drug users
• Occupational exposures (health care workers, laboratory personnel, Medical 
personnel, dental therapists, first aid providers)
• Anyone who comes in contact with infected blood
• Victims of sexual assault
The passive and active HBV immunisation is 95% effective in preventing estab-
lishment of chronic infection, but HBV reinfection is possible following continuous 
exposure to the virus.
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2. Hepatitis C virus
Hepatitis C virus (HCV) belongs to the Flaviviridae family and the genus 
Hepacivirus [39]; and has evolved over hundreds and thousands of years with 
human as the only host. When HCV was first identified in 1989 [40] as the aetio-
logical agent of non-A/non-B hepatitis the extent of the global health problem 
from HCV related cirrhosis and hepatocellular carcinoma was underestimated. 
Today HCV remains a global public health problem with a prevalence at 2.8%, with 
relatively low prevalence in Europe (0.6–5.6%), with pockets of high prevalence in 
Africa (Egypt has the highest prevalence rate estimated at 14% based on anti-HCV 
antibody testing) [41].
2.1 Discovery
HCV was discovered in 1989 [40]. It was thought to be the primary cause of 
transfusion-associated non-A/non-B hepatitis (NANBH). Following intensive 
search through development of different immunological and serological assays, an 
experimental chimpanzee model was utilised to identify the presence of an NANBH 
transmissible agent. Immunoscreening of bacterial complementary deoxyribonu-
cleic acid (cDNA) obtained from chimpanzee blood samples that were infected with 
NANBH enabled the isolation of a single cDNA clone, and the translation of viral 
proteins was possible. On 21st April 1989, Michael Houghton and his colleagues in 
collaboration with Daniel Bradley announced the discovery of NANBH aetiological 
agent and named it ‘Hepatitis C virus’ [40].
2.2 Properties
2.2.1 Structure
HCV is a small, enveloped virus that contains two viral glycoproteins expressed 
on the surface of the virus particle namely, E1 and E2 [42, 43]. The HCV is a 
positive-sense single-stranded RNA (+ssRNA) virus that has approximately 10,000 
bases in length. Visualised viral particles are estimated to be between 40 and 60 nm 
[44]. The HCV gene sequence contains a single long open reading frame (ORF) 
that produces large polyprotein precursor of more than 3000 amino acids. The 
HCV ORF is flanked by 5′ and 3′ non-translated regions (NTRs). During and after 
translation, the polyprotein precursor is cleaved by the proteases for synthesis of 
mature structural and non-structural (NS) proteins [45].
2.2.2 Lipoviral particle
The hepatic portal vein and hepatic arteries circulate blood through the liver. 
The HCV particles circulating in the blood stream are reported to bind directly 
to low density lipoprotein (LDL), very low density lipoprotein (VLDL), chylo-
microns, different types of apolipoproteins (apo) [46, 47]. The lipoviral particles 
(LVPs) are highly infectious viral particles that form a complex with VLDL com-
posed of triglyceride-rich, and cholesterol-rich lipoproteins that are believed to 
contain apoA1, apoB, apoC1, and apoE [48, 49]. During the LVPs formation they 
also form a complex with viral envelope glycoproteins E1 and E2; and nucleocap-
sids [50–52]. It is believed that the LVPs facilitate the viral attachment and entry 
into the target host cell [53].
Figure 2 shows an HCV viral particle in association with lipoproteins in a 
structure termed ‘lipoviral particle.’ The viral envelope glycoproteins E1, and E2 
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help to attach the virus to the host cell receptors. The apolipoprotein components of 
the LVPs are also facilitate viral binding via cellular lipoprotein receptors. (Adapted 
from https://pearl.plymouth.ac.uk/handle/10026.1/10386).
2.2.3 Replication
The primary in vivo target of HCV replication are hepatocytes, however, lack of 
small animal model to propagate HCV hampers efforts to fully describe the HCV 
replication.
Following the formation of LVPs in vascular compartment, they travel to the 
liver for attachment to the hepatocytes utilising the viral envelope glycoproteins, 
and the lipoprotein plasma lipoproteins component of the LVPs. The HCV LVP 
levels determine viral persistence [54]. The viral particles utilise the virally encoded 
envelope glycoproteins E1 and E2, and different classes of apolipoproteins (apoA-
1, apoB, apoC-1 and apoE) to bind to host cellular receptors, co-receptors, and 
entry factors to facilitate viral entry into the cell cytoplasm [53]. Some of the 
reported host cellular receptors and entry factors include: tetraspanin CD81, highly 
sulphated glycosaminoglycans (HS-GAGs) [55], low density lipoprotein receptor 
(LDLR), and Scavenger receptor class B type I (SR-BI) [56]. The viral entry involves 
clathrin-mediated endocytosis, and membrane fusion.
After entry, the viral RNA genome is translated for production of different 
viral proteins in endoplasmic reticulum (ER). Translation is of the polyprotein 
from HCV RNA is an essential first step after releasing the viral genetic material 
into the host cytoplasm. Since the HCV RNA is a positive-sense single strand, it 
directly serves as a template for translation. The 5′ NTR serves as the primary site 
where HCV RNA translation into polypeptides is initiated which results in expres-
sion of structural and NS viral proteins (NS1, 2, 3, 4 and 5) required for genome 
replication [52].
Several HCV NS proteins such as NS3/4A, NS4B, NS5A, and NS5B form part 
of a complex replication machinery which replicate a positive-sense RNA genome 
Figure 2. 
Hepatitis C virus lipoviral structure.
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through a negative-sense RNA intermediate which takes place in lipid droplets 
(LDs) [57]. The HCV replication process occurs in specialised membranous web 
on the endoplasmic reticulum membrane. Initiation of assembly of viral proteins 
requires release of viral genomes from the membranous web to the cytosolic site of 
the ER. Therefore, progeny viral assembly initiates in the cytosol followed by matu-
ration and release of the viral particles on the lumenal side of the ER membrane. 
During this process, the virions become lipidated through further interaction with 
the host lipid components, transported through the Golgi apparatus. After budding, 
the viral particles are transported to the extracellular environment through the lipid 
secretory channels [58].
2.3 HCV epidemiology, genotypes, and global distribution
HCV is one of the major causes of liver disease globally. Over the years HCV 
prevalence rates have increased to 2.8% worldwide, where an estimated 71 million 
people are reported to have chronic hepatitis C infection [59]. The World Health 
Organisation (WHO) estimates that nearly 399,000 people die annually due to 
HCV related liver disease. The HCV global distribution varies with high prevalence 
rates reported among people who inject drugs (PWIDs) [60]. Egypt has the highest 
burden of HCV infection due to use of non-sterile injecting needles during the mass 
treatment of schistosomiasis. In the 80s, the tartar emeric treatment was replaced 
by an oral drug, praziquantel for treatment of schistosomiasis [41].
Seven major HCV genotypes (1–7) were reported that comprise different sub-
species [61]. Determination of HCV genotypes is essential and predicts the disease 
outcome, and treatment options. Globally, HCV genotype 1 is the most prevalence, 
followed by genotypes 3, 2, and 4. Genotypes 1, 2, and 3 have a worldwide distribu-
tion but predominantly highly prevalent in western countries [62, 63]. Genotype 4 
is prevalent in Egypt and the middle-east, genotype 5 is prevalent in South Africa, 
and genotype is high in Hongkong. Genotype 6 is endemic in Southeast Asia  
[64, 65], whereas genotype 7 is was reported in central Africa [66].
The HCV nucleotide sequences show some genetic differences from one geno-
type to another. Genotypes show nearly 30% sequence diversity from each other 
[30, 67].
2.4 Transmission
HCV is primarily transmitted via parenteral exposure to the virus, though 
sometimes it can be transmitted sexually. Injection drug use (IDU) remains the 
highest risk factor for HCV infection in western countries. Some of the risk fac-
tors for HCV transmission include: blood transfusion before initiation of univer-
sal donor screening programme in 1991 [68], occupational exposure, tattooing, 
organ transplant from an infected donor, acupunctures, haemodialysis, and use of 
unsterilized razor blades and other paraphernalia for cultural rituals. Some stud-
ies have reported vertical transmission, as well as cell-to-cell transmission. The 
frequency of mother-to-child transmission is estimated at between 3 and 10% 
in some studies. The following factors have not been described to transmit HCV; 
hugging, kissing, hand shake, and/or sharing drinking bottles with an infected 
person [69].
2.5 HCV natural history
Exposure to HCV usually results in an asymptomatic acute HCV infection 
which is followed by three possible outcomes: clearance of the virus spontaneously 
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(15–25%), progression to chronic HCV infection (>80%), or remain uninfected 
without detectable HCV RNA and anti-HCV antibodies [70–72].
2.5.1 Acute HCV infection
Diagnosis of acute HCV infection is problematic because the majority of 
infected individuals are asymptomatic with only 20–30% go on to develop 
clinical signs and symptoms. An acute infection occurs during the first 
6 months following exposure, and during this period few infected individuals 
complain of fever, fatigue, nausea, anorexia, vomiting, and sometimes mild 
jaundice appears [73].
The HCV incubation period ranges from 3 to 12 weeks. The development of 
clinical manifestations depends on multiple viral and host factors that may include: 
infective dose (viral load), viral genotype, route of transmission, gender, age, 
and host immune response among others. HCV seroconversion window period 
ranges between 8 and 12 weeks after viremia. Of note, acute HCV infection does 
not always lead to the development of chronic infection. Nearly 20% of acute HCV 
infected individuals resolve the infection spontaneously with detectable anti-HCV 
antibodies, but without HCV RNA [73].
2.5.2 Chronic HCV infection
Following the establishment of acute HCV infection, nearly 80% of infected 
individuals progress to develop chronic HCV infection. Persistent HCV infection 
is usually associated with progressive hepatitis disease, with detectable HCV 
RNA and anti-HCV antibodies. Despite detection of HCV markers in the blood, 
there is no correlation between viremia and disease severity. The majority of 
chronically infected individuals develop fibrosis, cirrhosis and hepatocellular 
carcinoma (usually after 20 or more years followed infection) if no antiviral 
treatment is initiated. Once cirrhosis develops, the situation is usually irre-
versible but further liver damage can be prevented with early diagnosis and 
treatment. The development of cirrhosis and HCC is accelerated by immunosup-
pression [74]. Chronic HCV infection causes several histological changes in the 
liver and classifies the disease into persistent HCV infection, and active HCV 
infection with or without cirrhosis.
HCV infected individuals do not realise that they are infected, until the follow-
ing signs and symptoms appear: anorexia, vomiting, fever, dark urine, jaundice, 
weight loss, and myalgia.
2.6 Laboratory diagnosis
Since seroconversion takes 8–12 weeks after viremia, serological diagnosis 
of acute HCV infection is tricky. During the acute stage, molecular diagnostic 
methods are reliable where HCV RNA can be detected within 1–3 weeks after 
exposure. Anti-HCV antibodies can be detected at the onset of clinical signs 
and symptoms. The HCV laboratory diagnostic methods include detection of 
specific anti-HCV antibodies, quantification of HCV RNA, and characterisa-
tion of HCV biomarkers. Enzyme immunoassay (EIA), rapid diagnostic kits, 
and polymerase chain reaction (PCR) techniques are commonly used for HCV 
diagnosis. It is prudent that each facility should establish a testing algorithm that 
includes screening, supplementary, and confirmatory testing methods. Detection 
of HCV RNA confirms active infection, whereas detection of anti-HCV anti-
bodies suggests clearance of HCV infection spontaneously or establishment of 
Hepatitis B and C
14
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
chronic infection. It is advisable to confirm all anti-HCV positive test results with 
a nucleic acid test to rule-out spontaneous viral clearance [75]. Once chronic 
infection has been noted, further liver damage has to be assessed by performing 
liver function tests, liver biopsy, or other non-invasive procedures. In chronic 
HCV infection, the following markers are elevated: alanine transaminase (ALT), 
aspartate transaminase (AST), alkaline phosphatase (ALP), total protein  
(TP), gamma-glutamyl transpeptidase (GGT), prothrombin time (PT), total 
bilirubin, and sometimes a fasting serum acid [76].
2.7 Treatment, prevention, and control
For the past few decades, the standard HCV treatment has been interferon 
based therapy but there were increased cases of adverse effects, and reduced 
sustained viral response rate (50%). It is not all HCV cases that require treat-
ment, since some individuals are asymptomatic. When treatment is desirable, the 
primary goal is cure [77]. The arrival of direct acting antivirals (DAAs) since 2014 
with a high rate of responses to this treatment has brought a great expectancy of 
the possible cure and eradication of HCV infection in the next future. The WHO 
recommends sofosbuvir, daclatasvir, and the sofosbuvir/ledipasvir combination 
that has a 95% reported cure rate. Detection of the HCV genotypes and subtypes 
is relevant to response to the DAAs. The DAAs disrupt viral replication which sub-
sequent establishment of HCV infection [78]. The following classes of DAAs have 
been suggested: NS3/4A protease inhibitors, NS5A inhibitors, NS5B nucleoside 
polymerase (NS5B RNA-dependent RNA polymerase) inhibitors, and NS5B non-
nucleoside polymerase inhibitors. The DAAs have reduced the treatment duration 
(12 weeks to achieve cure), changed the drug administration route, reduced 
adverse effects, improved efficacy, viral sustained response, and tolerability [30]. 
Access to DAAs is still limited in low income countries, but the introduction of 
generic versions of DAAs has reduced the production and consumption cost in 




Faculty of Biomedical Science and Health Professions, University of Malawi College 
of Medicine, Blantyre, Malawi
*Address all correspondence to: ishawa@medcol.mw
15
Hepatitis B and C Viruses
DOI: http://dx.doi.org/10.5772/intechopen.82772
[1] Chisari FV, Isogawa M, Wieland 
SF. Pathogenesis of Hepatitis B virus 
infection. Pathologie et Biologie. 
2010;58:258-266. DOI: 10.1016/j.
patbio.2009.11.001.Pathogenesis
[2] Gilbert RJC, Beales L, Blond D, 
Simon MN, Lin BY, Chisari FV, et 
al. Hepatitis B small surface antigen 
particles are octahedral. In: Proceedings 
of the National Academy of Sciences. 
2005. DOI: 10.1073/pnas.0505062102
[3] Hu J, Liu K. Complete and 
incomplete hepatitis B virus particles: 
Formation, function, and application. 
Viruses. 2017. DOI: 10.3390/v9030056
[4] Shih C, Yang CC, Choijilsuren G, 
Chang CH, Liou AT. Hepatitis B virus. 
Trends in Microbiology. 2018. DOI: 
10.1016/j.tim.2018.01.009
[5] Zhang ZH, Wu CC, Chen XW, Li 
X, Li J, Lu MJ. Genetic variation of 
hepatitis B virus and its significance 
for pathogenesis. World Journal of 
Gastroenterology. 2016;22:126-144. 
DOI: 10.3748/wjg.v22.i1.126
[6] Lin CL, Kao JH. Natural history 
of acute and chronic hepatitis B: The 
role of HBV genotypes and mutants. 
Best Practice & Research. Clinical 
Gastroenterology. 2017;31:249-255. DOI: 
10.1016/j.bpg.2017.04.010
[7] Lok AS, Zoulim F, Dusheiko G, 
Ghany MG. Hepatitis B cure: From 
discovery to regulatory approval. 
Hepatology. 2017;66:1296-1313. DOI: 
10.1002/hep.29323
[8] Locarnini S, Zoulim F. Molecular 
genetics of HBV infection. Antiviral 
Therapy. 2010. DOI: 10.3851/IMP1619
[9] Testoni B, Durantel D, Zoulim F. 
Novel targets for hepatitis B virus 
therapy. Liver International. 2017. DOI: 
10.1111/liv.13307
[10] Seeger C, Mason WS. Molecular 
biology of hepatitis B virus infection. 
Virology. 2015. DOI: 10.1016/j.
virol.2015.02.031
[11] Frentzen A, Anggakusuma GE, 
Hueging K, Knocke S, Ginkel C, et al. 
Cell entry, efficient RNA replication, 
and production of infectious hepatitis 
C virus progeny in mouse liver-derived 
cells. Hepatology. 2014. DOI: 10.1002/
hep.26626
[12] Blondot ML, Bruss V, Kann M. 
Intracellular transport and egress of 
hepatitis B virus. Journal of Hepatology. 
2016. DOI: 10.1016/j.jhep.2016.02.008
[13] World Health Organization. 
Hepatitis B. WHO. 2018. https://www.
who.int/news-room/fact-sheets/detail/
hepatitis-b [Accessed: January 2, 2019]
[14] Zampino R, Boemio A, Sagnelli 
C, Alessio L, Adinolfi LE, Sagnelli 
E, et al. Hepatitis B virus burden in 
developing countries. World Journal of 
Gastroenterology. 2015;21:11941-11953. 
DOI: 10.3748/wjg.v21.i42.11941
[15] Tsai KN, Kuo CF, Ou JHJ. 
Mechanisms of Hepatitis B virus 
persistence. Trends in Microbiology. 
2018. DOI: 10.1016/j.tim.2017.07.006
[16] Nelson NP, Easterbrook PJ, 
McMahon BJ. Epidemiology of 
Hepatitis B virus infection and impact 
of vaccination on disease. Clinics in 
Liver Disease. 2016. DOI: 10.1016/j.
cld.2016.06.006
[17] Sunbul M. Hepatitis B virus 
genotypes: Global distribution and 
clinical importance. World Journal of 
Gastroenterology. 2014. DOI: 10.3748/
wjg.v20.i18.5427
[18] Ott JJ, Stevens GA, Groeger J, 
Wiersma ST. Global epidemiology 
of Hepatitis B virus infection: New 
References
Hepatitis B and C
16
estimates of age-specific HBsAg 
seroprevalence and endemicity. Vaccine. 
2012;30:2212-2219. DOI: 10.1016/j.
vaccine.2011.12.116
[19] Nayagam S, Thursz M, Sicuri E, 
Conteh L, Wiktor S, Low-Beer D, et al. 
Requirements for global elimination 
of hepatitis B: A modelling study. 
The Lancet Infectious Diseases. 
2016;16:1399-1408. DOI: 10.1016/
S1473-3099(16)30204-3
[20] Chang MH. Hepatitis B virus 
infection. In: Suchy FJ, Sokol RJ, 
Balistreri WF, editors. Liver Disease 
in Children. 4th ed. Cambridge, 
England, UK: Cambridge University 
Press; 2014. pp. 176-294. DOI: 10.1017/
CBO9781139012102.019
[21] Liaw YF. Natural history of 
chronic hepatitis B virus infection. 
In: Thomas HC, ASF L, editors. Viral 
Hepatitis. 4th ed. Hoboken, New Jersey, 
USA: Wiley; 2013. pp. 143-153. DOI: 
10.1002/9781118637272.ch10
[22] Lampertico P, Agarwal K, Berg T, 
Buti M, Janssen HLA, Papatheodoridis 
G, et al. EASL 2017 Clinical Practice 
Guidelines on the management of 
hepatitis B virus infection. Journal 
of Hepatology. 2017. DOI: 10.1016/j.
jhep.2017.03.021
[23] Bowden S. Hepatitis B virus. 
In: Carter IW, Schuller M, James 
GS, Sloots TP, Halliday CL, editors. 
PCR for Clinical Microbiology: 
An Australian and International 
Perspective Illustrate. Berlin, 
Germany: Springer Science & 
Business Media; 2010. DOI: 
10.1007/978-90-481-9039-3_36
[24] Wang FS, Shi JJ. 
Immunopathogenesis of hepatitis 
B virus (HBV) infection. In: Kao 
J-H, Chen D-S, editors. Hepatitis B 
Virus and Liver Disease. Singapore: 
Springer; 2018. pp. 45-62. DOI: 
10.1007/978-981-10-4843-2_3
[25] Baumert TF, Thimme R, von 
Weizsäcker F. Pathogenesis of hepatitis 
B virus infection. World Journal of 
Gastroenterology. 2007. DOI: 10.3748/
wjg.v13.i1.82
[26] Ferrari C. HBV and the immune 
response. Liver International. 2015. 
DOI: 10.1111/liv.12749
[27] Busca A, Kumar A. Innate immune 
responses in hepatitis B virus (HBV) 
infection. Virology Journal. 2014. DOI: 
10.1186/1743-422X-11-22
[28] Tawar RG, Colpitts CC, Timm J, 
Fehm T, Roggendorf M, Meisel H, et al. 
Acute hepatitis C virus infection induces 
anti-host cell receptor antibodies 
with virus-neutralizing properties. 
Hepatology. 2015;62:726-736. DOI: 
10.1002/hep.27906
[29] Cornberg M, Wong VWS, Locarnini 
S, Brunetto M, Janssen HLA, Chan 
HLY. The role of quantitative hepatitis 
B surface antigen revisited. Journal 
of Hepatology. 2017. DOI: 10.1016/j.
jhep.2016.08.009
[30] Razavi H, Robbins S, Zeuzem 
S, Negro F, Buti M, Duberg AS, 
et al. Hepatitis C virus prevalence 
and level of intervention required 
to achieve the WHO targets for 
elimination in the European Union by 
2030: A modelling study. The Lancet 
Gastroenterology & Hepatology. 
2017;2:325-336. DOI: 10.1016/
S2468-1253(17)30045-6
[31] Kwon HK, Lok ASF. Treatment of 
hepatitis B. In: Thomas HC, Lok ASF, 
Locarnini SA, Zuckerman AJ, editors. 
Viral Hepatitis. 4th ed., Hoboken, New 
Jersey, USA: Wiley; 2013. pp. 188-202. 
DOI: 10.1002/9781118637272.ch14.
[32] Dwyre DM, Holland PV. Hepatitis 
viruses. In: Barbara JAJ, Regan FAM, 
Contreras M, editors. Transfusion 
Microbiology. Cambridge, England, 
UK: Cambridge University Press; 
17
Hepatitis B and C Viruses
DOI: http://dx.doi.org/10.5772/intechopen.82772
2008. pp. 9-24. DOI: 10.1017/
CBO9780511545245.005
[33] Gerlich WH. Medical virology of 
hepatitis B: How it began and where we 
are now. Virology Journal. 2013;10:239. 
DOI: 10.1186/1743-422X-10-239
[34] Bonanni P, Pesavento G, Bechini 
A, Tiscione E, Mannelli F, Benucci C, 
et al. Impact of universal vaccination 
programmes on the epidemiology of 
hepatitis B: 10 years of experience in 
Italy. Vaccine. 2003. DOI: 10.1016/
S0264-410X(02)00580-7
[35] Mangen MJJ, Stibbe H, Urbanus A, 
Siedenburg EC, Waldhober Q, de Wit 
GA, et al. Targeted outreach hepatitis B 
vaccination program in high-risk adults: 
The fundamental challenge of the last 
mile. Vaccine. 2017. DOI: 10.1016/j.
vaccine.2017.04.068
[36] Centers for Disease Control and 
Prevention. Hepatitis B vaccination—
United States, 1982-2002. Morbidity 
and Mortality Weekly Report. 2002
[37] Pileggi C, Papadopoli R, Bianco A, 
Pavia M. Hepatitis B vaccine and the 
need for a booster dose after primary 
vaccination. Vaccine. 2017. DOI: 
10.1016/j.vaccine.2017.09.076
[38] Bruce MG, Bruden D, Hurlburt 
D, Zanis C, Thompson G, Rea L, et al. 
Antibody levels and protection after 
Hepatitis B vaccine: Results of a 30-year 
follow-up study and response to a 
booster dose. The Journal of Infectious 
Diseases. 2016. DOI: 10.1093/infdis/
jiv748
[39] Pybus OG, Barnes E, Taggart R, 
Lemey P, Markov PV, Rasachak B, 
et al. Genetic history of hepatitis C 
virus in East Asia. Journal of Virology. 
2009;83:1071-1082. DOI: 10.1128/
JVI.01501-08
[40] Choo QL, Kuo G, Weiner a J, Overby 
LR, Bradley DW, Houghton M. Isolation 
of a cDNA clone derived from a blood-
borne non-A, non-B viral hepatitis 
genome. Science. 1989;244:359-362
[41] Lehman EM, Wilson ML. 
Epidemiology of hepatitis viruses 
among hepatocellular carcinoma 
cases and healthy people in Egypt: A 
systematic review and meta-analysis. 
International Journal of Cancer. 
2009;124:690-697. DOI: 10.1002/
ijc.23937
[42] Beaumont E, Roch E, Chopin L, 
Roingeard P. Hepatitis C virus E1 and E2 
proteins used as separate immunogens 
induce neutralizing antibodies with 
additive properties. PLoS One. 2016. 
DOI: 10.1371/journal.pone.0151626
[43] Chevaliez S, Pawlotsky J-M. HCV 
genome and life cycle. In: Tan S-L, 
editor. Hepatitis C Viruses: Genomes 
and Molecular Biology. Norfolk, UK: 
Horizon Bioscience; 2006. pp. 5-48. 
PMID: 21250393
[44] Baumert TF, Ito S, Wong DT, Liang 
TJ. Hepatitis C virus structural proteins 
assemble into viruslike particles 
in insect cells. Journal of Virology. 
1998;72:3827-3836
[45] Khan AG, Whidby J, Miller MT, 
Scarborough H, Zatorski AV, Cygan A, 
et al. Structure of the core ectodomain 
of the hepatitis C virus envelope 
glycoprotein 2. Nature. 2014. DOI: 
10.1038/nature13117
[46] Fukuhara T, Ono C, Puig-Basagoiti 
F, Matsuura Y. Roles of lipoproteins 
and apolipoproteins in particle 
formation of Hepatitis C virus. Trends 
in Microbiology. 2015. DOI: 10.1016/j.
tim.2015.07.007
[47] Yamamoto S, Fukuhara T, Ono C, 
Uemura K, Kawachi Y, Shiokawa M, et 
al. Lipoprotein receptors redundantly 
participate in entry of Hepatitis C virus. 
PLoS Pathogens. 2016. DOI: 10.1371/
journal.ppat.1005610
Hepatitis B and C
18
[48] Diaz O, Delers F, Maynard M, 
Demignot S, Zoulim F, Chambaz J, et 
al. Preferential association of Hepatitis 
C virus with apolipoprotein B48-
containing lipoproteins. The Journal of 
General Virology. 2006;87:2983-2991. 
DOI: 10.1099/vir.0.82033-0
[49] Felmlee DJ, Sheridan DA, Bridge 
SH, Nielsen SU, Milne RW, Packard 
CJ, et al. Intravascular transfer 
contributes to postprandial increase in 
numbers of very-low-density hepatitis 
C virus particles. Gastroenterology. 
2010;139:1774-1783, 1783.e1-6. DOI: 
10.1053/j.gastro.2010.07.047
[50] Kong L, Giang E, Nieusma T, 
Kadam RU, Cogburn KE, Hua Y, et 
al. Hepatitis C virus E2 envelope 
glycoprotein core structure. Science. 
2013. DOI: 10.1126/science.1243876
[51] Dao Thi VL, Dreux M, Cosset F-L. 
Scavenger receptor class B type I and 
the hypervariable region-1 of hepatitis 
C virus in cell entry and neutralisation. 
Expert Reviews in Molecular 
Medicine. 2011;13:e13. DOI: 10.1017/
S1462399411001785
[52] Boyer A, Dumans A, Beaumont E, 
Etienne L, Roingeard P, Meunier J-C. 
The association of hepatitis C virus 
glycoproteins with apolipoproteins 
E and B early in assembly is 
conserved in lipoviral particles. The 
Journal of Biological Chemistry. 
2014;289:18904-18913. DOI: 10.1074/
jbc.M113.538256
[53] Shawa IT, Sheridan DA, Felmlee DJ, 
Cramp ME. Lipid interactions influence 
hepatitis C virus susceptibility and 
resistance to infection. Clinics in Liver 
Disease. 2017;10:17-20. DOI: 10.1002/
cld.643
[54] Sheridan DA, Hajarizadeh B, 
Fenwick FI, Matthews GV, Applegate 
T, Douglas M, et al. Maximum levels 
of hepatitis C virus lipoviral particles 
are associated with early and persistent 
infection. Liver International. 2016;23. 
DOI: 10.1111/liv.13176
[55] Barth H, Schafer C, Adah MI, 
Zhang F, Linhardt RJ, Toyoda H, 
et al. Cellular binding of hepatitis 
C virus envelope glycoprotein E2 
requires cell surface heparan sulfate. 
The Journal of Biological Chemistry. 
2003;278:41003-41012. DOI: 10.1074/
jbc.M302267200
[56] Ramasamy I. Recent advances in 
physiological lipoprotein metabolism. 
Clinical Chemistry and Laboratory 
Medicine. 2014;52:1695-1727. DOI: 
10.1515/cclm-2013-0358
[57] Filipe A, McLauchlan J. Hepatitis 
C virus and lipid droplets: Finding a 
niche. Trends in Molecular Medicine. 
2015;21:34-42. DOI: 10.1016/j.
molmed.2014.11.003
[58] Bassendine MF, Sheridan 
DA, Bridge SH, Felmlee DJ, Neely 
RDG. Lipids and HCV. Seminars in 
Immunopathology. 2013;35:87-100. 
DOI: 10.1007/s00281-012-0356-2
[59] Mysore KR, Leung DH. Hepatitis 
B and C. Clinics in Liver Disease. 2018. 
DOI: 10.1016/j.cld.2018.06.002
[60] Nelson PK, Mathers BM, Cowie B, 
Hagan H, Des Jarlais D, Horyniak D, 
et al. Global epidemiology of hepatitis 
B and hepatitis C in people who inject 
drugs: Results of systematic reviews. 
Lancet. 2011;378:571-583. DOI: 10.1016/
S0140-6736(11)61097-0
[61] Bukh J. The history of hepatitis C 
virus (HCV): Basic research reveals 
unique features in phylogeny, evolution 
and the viral life cycle with new 
perspectives for epidemic control. 
Journal of Hepatology. 2016;65:S2-S21. 
DOI: 10.1016/j.jhep.2016.07.035
[62] Messina JP, Humphreys I, Flaxman 
A, Brown A, Cooke GS, Pybus OG, et al. 
Global distribution and prevalence of 
19
Hepatitis B and C Viruses
DOI: http://dx.doi.org/10.5772/intechopen.82772
hepatitis C virus genotypes. Hepatology. 
2015;61:77-87. DOI: 10.1002/hep.27259
[63] Esteban JI, Sauleda S, Quer J. The 
changing epidemiology of hepatitis C 
virus infection in Europe. Journal of 
Hepatology. 2008;48:148-162. DOI: 
10.1016/j.jhep.2007.07.033
[64] Bunchorntavakul C, 
Chavalitdhamrong D, Tanwandee 
T. Hepatitis c genotype 6: A concise 
review and response-guided therapy 
proposal. World Journal of Hepatology. 
2013;5:496-504. DOI: 10.4254/wjh.
v5.i9.496
[65] Thong VD, Akkarathamrongsin 
S, Poovorawan K, Tangkijvanich 
P, Poovorawan Y. Hepatitis C virus 
genotype 6: Virology, epidemiology, 
genetic variation and clinical 
implication. World Journal of 
Gastroenterology. 2014;20:2927-2940. 
DOI: 10.3748/wjg.v20.i11.2927
[66] Murphy DG, Sablon E, 
Chamberland J, Fournier E, Dandavino 
R, Tremblay CL. Hepatitis C virus 
genotype 7, a new genotype originating 
from Central Africa. Journal of Clinical 
Microbiology. 2015;53:967-972. DOI: 
10.1128/JCM.02831-14
[67] Petruzziello A, Marigliano S, 
Loquercio G, Cozzolino A, Cacciapuoti 
C. Global epidemiology of hepatitis 
C virus infection: An up-date of the 
distribution and circulation of hepatitis 
C virus genotypes. World Journal of 
Gastroenterology. 2016;22:7824-7840. 
DOI: 10.3748/wjg.v22.i34.7824
[68] Williams JL, Cagle HH, Christensen 
CJ, Fox-Leyva LK, McMahon BJ. Results 
of a hepatitis C general transfusion 
lookback program for patients who 
received blood products before July 
1992. Transfusion. 2005;45:1020-1026. 
DOI: 10.1111/j.1537-2995.2005.04280.x
[69] Gibb DM, Goodall RL, Dunn 
DT, Healy M, Neave P, Cafferkey M, 
et al. Mother-to-child transmission 
of hepatitis C virus: Evidence for 
preventable peripartum transmission. 
Lancet. 2000;356:904-907. DOI: 
10.1097/00006454-200106000-00025
[70] Shawa IT, Felmlee DJ, Hegazy D, 
Sheridan DA, Cramp ME. Exploration 
of potential mechanisms of HCV 
resistance in exposed uninfected 
intravenous drug users. Journal of Viral 
Hepatitis. 2017;24(12):1082-1088. DOI: 
10.1111/jvh.12720
[71] Thurairajah PH, Hegazy D, Chokshi 
S, Shaw S, Demaine A, Kaminski ER, et 
al. Hepatitis C virus (HCV)—Specific 
T cell responses in injection drug 
users with apparent resistance to HCV 
infection. The Journal of Infectious 
Diseases. 2008;198:1749-1755. DOI: 
10.1086/593337
[72] Mizukoshi E, Eisenbach C, Edlin 
BR, Newton KP, Raghuraman S, Weiler-
Normann C, et al. Hepatitis C virus 
(HCV)-specific immune responses 
of long-term injection drug users 
frequently exposed to HCV. The Journal 
of Infectious Diseases. 2008;198:203-
212. DOI: 10.1086/589510
[73] Ghany MG, Jake Liang T. Natural 
history of chronic hepatitis C. In: 
Miyamura T, Lemon S, Walker 
C, Wakita T, editors. Hepatitis C 
Virus II: Infection and Disease. 
Tokyo, Japan: Springer; 2016. DOI: 
10.1007/978-4-431-56101-9_1
[74] Hoshida Y, Fuchs BC, Bardeesy N, 
Baumert TF, Chung RT. Pathogenesis 
and prevention of hepatitis C 
virus-induced hepatocellular 
carcinoma. Journal of Hepatology. 
2014;61:S79-S90. DOI: 10.1016/j.
jhep.2014.07.010
[75] Esteban-Riesco L, Depaulis F, 
Moreau A, Bacq Y, Dubois F, Goudeau 
A, et al. Rapid and sustained autologous 
neutralizing response leading to early 
spontaneous recovery after HCV 
Hepatitis B and C
20
infection. Virology. 2013;444:90-99. 
DOI: 10.1016/j.virol.2013.05.037
[76] Bunchorntavakul C, Jones LM, 
Kikuchi M, Reddy KR, Chang K. 
Distinct features in natural history 
and outcomes of acute Hepatitis C. 
Journal of Clinical Gastroenterology. 
2015;49(4):e31-e40
[77] Li HC, Lo SY. Hepatitis C virus: 
Virology, diagnosis and treatment. 
World Journal of Hepatology. 
2015;7:1377-1389. DOI: 10.4254/wjh.
v7.i10.1377
[78] De Monte A, Courjon J, Anty R, 
Cua E, Naqvi A, Mondain V, et al. 
Direct-acting antiviral treatment in 
adults infected with hepatitis C virus: 
Reactivation of hepatitis B virus 
coinfection as a further challenge. 
Journal of Clinical Virology. 2016;78:27-
30. DOI: 10.1016/j.jcv.2016.02.026
[79] Kondili LA, Robbins S, Blach S, 
Gamkrelidze I, Zignego AL, Brunetto 
MR, et al. Forecasting Hepatitis C liver 
disease burden on real-life data. Does 
the hidden iceberg matter to reach the 
elimination goals? Liver International. 
2018;38:2190-2198. DOI: 10.1111/
liv.13901
